[go: up one dir, main page]

CN107206078A - 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 - Google Patents

特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 Download PDF

Info

Publication number
CN107206078A
CN107206078A CN201580075642.0A CN201580075642A CN107206078A CN 107206078 A CN107206078 A CN 107206078A CN 201580075642 A CN201580075642 A CN 201580075642A CN 107206078 A CN107206078 A CN 107206078A
Authority
CN
China
Prior art keywords
seq
probdnf
antibody
mouse
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580075642.0A
Other languages
English (en)
Inventor
李昌琪
王华茂
戴茹萍
蔡秀梅
周新富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yile Biotechnology Ltd
Original Assignee
Shanghai Yile Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yile Biotechnology Ltd filed Critical Shanghai Yile Biotechnology Ltd
Publication of CN107206078A publication Critical patent/CN107206078A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了特异性结合脑源性神经营养因子前体蛋白(proBDNF)的结合分子的应用。所述proBDNF的结合分子，特别是proBDNF的单克隆抗体，能够用于预防、缓解或治疗自身免疫性疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201580075642.0A 2014-12-19 2015-12-18 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 Pending CN107206078A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014108116788 2014-12-19
CN201410811678.8A CN105770889B (zh) 2014-12-19 2014-12-19 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
PCT/CN2015/097820 WO2016095839A1 (zh) 2014-12-19 2015-12-18 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Publications (1)

Publication Number Publication Date
CN107206078A true CN107206078A (zh) 2017-09-26

Family

ID=56125955

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410811678.8A Active CN105770889B (zh) 2014-12-19 2014-12-19 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
CN201580075642.0A Pending CN107206078A (zh) 2014-12-19 2015-12-18 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410811678.8A Active CN105770889B (zh) 2014-12-19 2014-12-19 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Country Status (11)

Country Link
US (2) US10556947B2 (zh)
EP (1) EP3235507B1 (zh)
JP (2) JP6758317B2 (zh)
KR (1) KR20170104487A (zh)
CN (2) CN105770889B (zh)
AU (1) AU2015366363B2 (zh)
CA (1) CA2971823A1 (zh)
ES (1) ES2826523T3 (zh)
MX (1) MX2017007970A (zh)
SG (1) SG11201705004VA (zh)
WO (1) WO2016095839A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
CN118085080A (zh) * 2024-02-28 2024-05-28 湖南永和阳光生物科技股份有限公司 一种检测神经退行性疾病的单克隆抗体组合物及其制备方法与应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105770889B (zh) 2014-12-19 2021-06-01 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
JP2020531041A (ja) * 2017-08-28 2020-11-05 上海易楽生物技術有限公司 ポリペプチドとポリペプチドに結合される抗体
CN114660296B (zh) * 2020-12-23 2025-07-15 深圳市安群生物工程有限公司 一种脑源性神经营养因子测定试剂盒及其应用和脑源性神经营养因子特异性抗体
CN112574305B (zh) * 2020-12-30 2022-04-22 深圳清华大学研究院 针对前体脑源性神经营养因子的抗体及其应用
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093904A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN104774264A (zh) * 2014-01-15 2015-07-15 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506963B2 (en) 2009-09-22 2013-08-13 Shanghai Cancer Institute Anti-EFGRv3 monoclonal antibody
CN105770889B (zh) 2014-12-19 2021-06-01 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093904A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN104774264A (zh) * 2014-01-15 2015-07-15 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
罗雁威 等: "脑源性神经营养因子前体蛋白生物学效应研究进展", 《现代生物医学进展》 *
许春向 等: "《现代卫生化学》", 29 February 2000, 人民卫生出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
CN118085080A (zh) * 2024-02-28 2024-05-28 湖南永和阳光生物科技股份有限公司 一种检测神经退行性疾病的单克隆抗体组合物及其制备方法与应用

Also Published As

Publication number Publication date
JP2020200340A (ja) 2020-12-17
JP6758317B2 (ja) 2020-09-23
CA2971823A1 (en) 2016-06-23
AU2015366363B2 (en) 2021-09-02
HK1244712A1 (zh) 2018-08-17
JP2018502905A (ja) 2018-02-01
KR20170104487A (ko) 2017-09-15
EP3235507A1 (en) 2017-10-25
EP3235507A4 (en) 2018-06-20
CN105770889B (zh) 2021-06-01
MX2017007970A (es) 2018-04-13
ES2826523T3 (es) 2021-05-18
CN105770889A (zh) 2016-07-20
SG11201705004VA (en) 2017-07-28
US20210017264A1 (en) 2021-01-21
WO2016095839A1 (zh) 2016-06-23
US10556947B2 (en) 2020-02-11
US20170362313A1 (en) 2017-12-21
AU2015366363A1 (en) 2017-07-13
EP3235507B1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
CN107206078A (zh) 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
TWI757304B (zh) Lag-3抗體、其抗原結合片段及其醫藥用途
TWI608015B (zh) 具有組織標的功能的抗發炎分子
JP7499228B2 (ja) 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用
JP6463377B2 (ja) 抗ヒトｐｒｏＢＤＮＦモノクローナル抗体およびその疼痛における作用
RU2596403C2 (ru) Антитело к аннексину а1
KR20130060264A (ko) 위장관의 기능적 질환 또는 이상을 치료하는 제약학적 복합 조성물 및 방법들
CN108359011B (zh) 靶向于白介素17a的抗体、其制备方法和应用
CN109929035A (zh) 抗人ngf抗体及其制备方法和用途
US20240383980A1 (en) CD3/CD25 Antibodies For Neuro-Immune Diseases
BR112020003628A2 (pt) anticorpo anti-pacap
JP2852705B2 (ja) 自己免疫疾患の治療
US12209124B2 (en) Anti-IL-17A antibody and use thereof
WO2024160076A1 (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途
TW202144425A (zh) 特異性抗原結合分子，其製備方法及醫藥用途
TWI860191B (zh) 重組抗體、包含該重組抗體的藥學組合物及其於治療癌症之用途
US20250136674A1 (en) Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment
HK1244712B (zh) 用於特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
WO2020024931A1 (en) Anti-il-17a antibodies and use thereof
CN121226559A (zh) 双特异性抗体及其应用
WO2011153592A1 (en) Therapeutic molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170926